Mumbai based Epigeneres Biotech raises $6 million in Series B round of funding

• ByTejika Bajaj     |    January 20, 2022

Mumbai based startup Epigeneres Biotech has recently announced that it has raised a sum of $6 million in its Series B round of funding led by Kotak Investment Advisors, Moez Daya and LetsVenture Angel Fund. The round also saw participation from prominent investors including Ashish Kacholia, East River Advisors, One Decacorn, Nandita Advisors as well as Chockalingam Valliappa among others.

Talking about the recent round of fundraise, Ashish Tripathi, Founder & Chairman, Epigeneres said, “This latest round of financing will help us continue our upward trajectory in early detection of cancer. The investment will go toward expanding the R&D team, scaling operations, and development of new products, even as we continue bringing out the finest healthcare technologies and solutions. We have received very positive feedback from the market and with the help of our investors and the Government, we will soon begin to commercialise the cancer test; first in India, and then at a global level.”

The company officials have revealed that the recently infused capital will be deployed towards expansion of its lab facilities as well as to scale its operations. Furthermore, it also aims to utilise the funds for the development of an AI platform to launch its services in India as well as to bring the best diagnostic technology to patients and providers.

Speaking on the funding, Nitin Deshmukh of Kotak said, “The ability to detect cancer through a simple blood test at Stage Zero can be a major breakthrough that can change the way cancer diagnosis is approached. We see this as an excellent opportunity to partner in the pioneering growth story of a home-grown Indian company that is innovating diagnostic technologies in oncology.”

Follow Startup Story